A study published today in the September issue of the American Journal of Roentgenology finds that a combination of CT texture analysis of metastases, initial tumor size changes and serum biomarker lactate dehydrogenase is highly accurate in predicting the overall survival of patients with metastatic melanoma whose tumors fail to shrink significantly in response to bevacizumab therapy.
MRV Research
Non-invasive, laser doppler system detects skin cancer
Skin malignant melanoma is a highly angiogenic cancer – it develops via blood vessels – necessitating early diagnosis for positive prognosis. But the current diagnostic standard of biopsy and histological examination inevitably leads to many unnecessary invasive excisions.
Immune-related adverse events do not impact melanoma survival, time to treatment failure
Patients with melanoma treated with ipilimumab often experience immune-related adverse events; however, these events do not appear to impact patient survival or time to treatment failure, according to retrospective study results.
Fewer moles linked to more aggressive melanoma
HealthDay News — Individuals who have many moles are at increased risk for melanoma skin cancer, but those with fewer moles may be more likely to develop a more aggressive form of the disease, according to research scheduled for presentation at the American Academy of Dermatology’s 2015 Summer Academy Meeting, held from Aug. 19 to 23 in New York City.